Tag: LimFlow

Personalized postoperative anticoagulation needed to curb lower-limb amputations

“We’re going to see more and more amputations if we don’t figure out the right post procedure thromboprophylaxis regime ASAP,” Anahita Dua, MD, warned...

PROMISE II 12-month data show durable outcomes with the LimFlow system...

One-year results from the PROMISE II US pivotal trial demonstrate the durability of outcomes of transcatheter arterialisation of the deep veins (TADV) using the...
agreement

LimFlow announces agreement to be acquired by Inari Medical

LimFlow announced today that it has entered into a definitive agreement to be acquired by Inari Medical. A press release details that, under the terms...
top 10

The top 10 most popular Vascular Specialist stories of September 2023

Last month, the most read stories from Vascular Specialist included data releases from the recent Midwestern Vascular Surgical Society (MVSS) using direct revascularization of segmental...

FDA approves LimFlow system for ‘no-option’ CLTI patients

The Food and Drug Administration (FDA) today announced approval of LimFlow therapy—a novel and minimally invasive procedure designed to bypass blockages in arteries of...
LimFlow deep vein arterialization

Results from PROMISE II pivotal trial published, reinforcing ‘ transformational value’...

Results from the PROMISE II pivotal trial investigating transcatheter arterialization of the deep veins using the LimFlow system in so-called no-option chronic limb-threatening ischemia...
top 10

The 10 most popular Vascular Specialist stories of November 2022

Among November's most read Vascular Specialist stories were updates from the BEST-CLI trial in the form of new data and funding; a guest...

End-stage CLTI: Deep-vein arterialization procedure demonstrates amputation-free survival rate of 66%...

Six-month results from the PROMISE II trial of the LimFlow deep-vein arterialization system showed an overall amputation-free survival of 66%—“well above” the primary endpoint...

Treating PAD: ‘Run, don’t walk, to sign up for this incredible...

No matter if you’re a surgeon with a few years—or a few decades—of experience, faculty members of a new, upcoming Society for Vascular Surgery...

PROMISE II U.S. pivotal trial of device designed for ‘no-option’ CLTI...

Enrollment has been completed in the PROMISE II pivotal trial of the LimFlow deep vein arterialization system designed to prevent amputations in so-called "no-option"...

PROMISE I 24-month results ‘validate the benefits of the LimFlow system’

LimFlow has announced 24-month results from the PROMISE I study of the LimFlow percutaneous deep vein arterialization system, confirming “excellent and sustained outcomes” for...

LimFlow system a ‘cost-effective and high-value alternative’ to traditional therapies

Percutaneous deep vein arterialization (pDVA) with the LimFlow system offers a cost-effective and high-value alternative to traditional therapies or amputation, according to a recent...

One-year results from PROMISE I study of LimFlow system in ‘no-option’...

Twelve-month data from the full patient cohort in the PROMISE I study of the LimFlow percutaneous deep vein arterialization (pDVA) system have been...

Positive two-year data from ALPS registry of LimFlow system published

LimFlow SA today announced publication of positive two-year data from the ALPS registry of the LimFlow percutaneous deep vein arterialization (pDVA) system. Results were published...